Received Apr 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | — | — |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | 1 | — | — |
patient is a 4 y.o. female who presents for evaluation of a skin concern involving the face and torso that the patient's father describes as a rash. Historian : Father. This concern started within the last hour prior to arrival. She has also had a cough and runny nose for the last 48 hours. Appearance is raised, red, and round and is pruritic (minimally). Appearance has become more wide spread over time. Associated symptoms: cough and irritability. Patient has not had contacts with similar concern. Patient has recently received the MMRV vaccine as well as DTap, IPV, Hib, HepB, HepA, and PCV15 vaccines 4/2/25. Patient has tried nothing for treatment. Father states he has to clean out mucous from patient's eyes. Temp is 99.1F, HR 133, R 18, SpO2 98% on room air, wt 16.9 kg. Symptomatic management was recommended.
None
None
None
None
Positive measles PCR nasopharyngeal swab.